Pedro Gois

Chemical Biology

Chemical biology offers unique possibilities to rationally manipulate biological processes and will most certainly play a major role in unravelling solutions for current unmet medical needs. Broadly our laboratory is focusing on discovering innovative chemical technologies that permit the construction of functional molecules, and on applying these technologies to the construction of therapeutic bioconjugates and small molecule probes.

Emerging technologies

Inspired by Nature’s repertoire of functional molecules, our laboratory is developing new chemical technologies to synthesise functional small molecules and bioconjugates to study and interfere in disease biological mechanisms that are critical for therapeutic interventions.

Oncology

We are designing new formats of bioconjugates for drug delivery for oncology. The focus is to discover new bioconjugation methods and linker technologies that may be used to generate targeting drug conjugates with more well-defined structures and with mechanisms that trigger a therapeutic action as a direct respond to the disease chemical environment.

Neurodegenerative diseases

Bioimaging of disease associated molecular mechanisms is a fundamental tool to discover new strategies for therapeutic intervention. We have developed a highly modular platform of fluorescent dyes (BASHY) that, in collaboration with neuroscientist at imed, are been used to elucidate the role of microglia in the clearance of myelin debris in multiple scleroses (MS). We hope with these studies to unravel new mechanisms that can be targeted to prevent and intervene therapeutically in MS.

Metabolic disorders

Protein misfolding is recognized as the main underlying pathogenic mechanism of different diseases. In this area we are developing small molecules that can be used as modulators of specific protein enrolled in genetic diseases like Phenylketonuria.

Lopes RR, Tomé CS, Russo R, Paterna R, Leandro J, Candeias NR, Gonçalves LMD, Teixeira M, Sousa PMF, Guedes RC, Vicente JB, Gois PMP, Leandro P. Modulation of human phenylalanine hydroxylase by 3-hydroxyquinolin-2(1H)-one derivatives. Biomolecules 2021; 11: 462. DOI: 10.3390/biom11030462
Silva MJSA, Faustino H, Coelho J, Pinto MV, Fernandes A, Compañón I, Corzana F, Gasser G, Gois PMP. Efficient amino‐sulfhydryl stapling on peptides and proteins using bifunctional NHS‐activated acrylamides. Angew. Chem. Int. Ed. 2021; 60: 10850. DOI: 10.1002/anie.202016936
Russo R, Padanha R, Fernandes F, Veiros L, Corzana F, Gois PMP. Engineering boron hot spots for the site-selective installation of iminoboronates on peptide chains. Chem. Eur. J. 2020; 26: 15226. DOI: 10.1002/chem.202002675
Santos FMF, Domínguez Z, Fernandes JPL, Carvalho CP, Collado D, Pèrez-Inestrosa E, Pinto MV, Fernandes A, Arteaga JF, Pischel U, Gois PMP. Cyanine-like Boronic Acid Derived Salicylidenehydrazone Complexes (Cy- BASHY) for Bioimaging Applications. Chem. Eur. J. 2020; 26: 14064. DOI: 10.1002/chem.202001623
Santos FMF, Matos AI, Ventura AE, Gonçalves J, Veiros LF, Florindo HF, Gois PMP. Modular Assembly of Reversible Multivalent Targeting Drug Conjugates. Angew. Chem. Int. Ed. 2017; 56: 9346. DOI: 10.1002/anie.201703492

Pedro Gois

Group Leader

Email: pedrogois@ff.ulisboa.pt

Phone: (+351) 217946400 (Ext. 14614)

View Profile
[lab_researchers_otherinfo_shortcode_output]
Back To Top
Come meet us at

Faculdade de Farmácia da Universidade de Lisboa | Av. Professor Gama Pinto
1649-003 Lisboa | Portugal


Phone | +351 217 946 400
Fax | +351 217 946 470
Web | www.imed.ulisboa.pt
Email | imed.ulisboa@ff.ulisboa.pt

Social